Khaled Musallam Applauds Hatoon Ezzat’s Leadership and Healthcare Advances in Saudi Arabia
Khaled Musallam, Group Chief Research Officer at Burjeel Holdings, reposted from Thalassaemia International Federation (TIF) on LinkedIn:
”Very impressed with all the tech and regulatory advances deployed by the Ministry of Health Saudi Arabia and the leadership of Dr Hatoon Ezzat dedicated to the management of inherited blood disorders in general and thalassemia in specific. Outcomes from such initiatives will surely have global implications on disease understanding and care.”
Quoting Thalassaemia International Federation (TIF)‘s post:
”High-Level TIF–Kingdom of Saudi Arabia Strategic Meeting | 14 December 2025
A high-level delegation of the Thalassaemia International Federation – TIF held a strategic meeting on 14 December 2025 with senior representatives of the Ministry of Health Saudi Arabia, underscoring a shared commitment to accelerating progress in the prevention, control, and comprehensive management of thalassaemia and other haemoglobinopathies.
The TIF delegation comprised Dr. Androulla Eleftheriou, TIF Executive Director; Prof. john porter, Professor of Haematology and Consultant Haematologist at University College London Hospitals (UK); Prof. Khaled Musallam, MD, PhD, Group Chief Research Officer of Burjeel Holdings and Founding Director of CR-RBD (UAE); and Prof. Dimitrios Farmakis, MD, PhD, FESC, FHFA, Professor of Cardiology at the National and Kapodistrian University of Athens (Greece), members of TIF’s International Scientific Advisory Board.
The delegates met with H.E. Dr. Mohammed K. Alabdulaali, Assistant Deputy Minister for Hospital Services; Dr. Hatoon Ezzat, Assistant Minister’s Advisor and General Supervisor of Blood Disorders; and Prof. Ahmad Tarawah, Consultant in Pediatric Hematology/Oncology.
During the discussions, TIF congratulated the Government of the KSA on its notable progress in strengthening national systems for the control and management of thalassaemia and other haemoglobinopathies, as well as on the impressive outcomes of its health-sector digitaltransformation.
Particular emphasis was placed on advancing integrated digital health ecosystems and strengthening datasystems, enabling smarter service planning, better follow-up, improved continuity of care, and a more streamlined patientjourney across different levels of the health system.
TIF also commended the KSA’s leadership in facilitating access to healthinnovation, including its distinction as the first country globally to authorise the novel oral therapy PYRUKYND® (mitapivat) for adult patients with transfusion-dependent (TDT) and non-transfusion-dependent (NTDT) α- or β-thalassaemia.
Building on an already excellent and long-standing collaboration between TIF and the KSA, the meeting also explored a forward-looking agenda of joint initiatives.
These include co-developed educational activities and collaborative actions that could support regional and international efforts to improve standards of care and outcomes for patients and their families.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers